All In Biotech

Drug Trial Radar · NCT05622708

A Study of Secukinumab to Evaluate Maintenance of Response in Participants With Non-radiographic Axial Spondyloarthritis Who Achieved Remission

A Multicenter Study of Secukinumab, With a Randomized Double-blind, Placebo-controlled Withdrawal-retreatment Period, to Evaluate Maintenance of Response in Participants With Non-radiographic Axial Spondyloarthritis Who Achieved Remission

Last checked: Nov 20, 2026Latest source record: Oct 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 240 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

240

Actual

Start

Mar 28, 2023

Primary completion

Feb 8, 2028

Study completion Apr 4, 2028

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Nov 21, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 100 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will establish whether prolonged chronic dosing with secukinumab is needed in participants with Non-radiographic axial spondyloarthritis, (nr-axSpA) who have achieved remission. Remission is defined as Ankylosing Spondylitis Disease Activity Score - C-reactive protein (ASDAS-CRP) Inactive Disease (ID) response (ASDAS-CRP \< 1.3). Maintenance of remission on continued secukinumab treatment will be evaluated compared to placebo using a randomized withdrawal design. The primary outcome measure for this study is the proportion of participants remaining flare-free at Week 120.

Conditions

  • Non-radiographic Axial Spondyloarthritis

Interventions

  • SecukinumabDrug

    Treatment Period 1: Open-label secukinumab 150 mg PFS s.c. at baseline, Weeks 1, 2, 3 and 4 followed by administration every four weeks up to Week 52.

  • PlaceboDrug

    Treatment Period 2: Double-blind placebo PFS s.c. every 4 weeks from Week 56 to Week 116.

  • SecukinumabDrug

    Treatment Period 2: Double-blind secukinumab 150 mg PFS s.c. every 4 weeks from Week 56 to Week 116. Escape re-treatment (during Treatment Period 2): Open-label secukinumab 150 mg PFS s.c.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The proportion of participants remaining flare-free during Treatment Period 2Time frame: Week 120

Locations

61 sites in 18 countries. Site status is shown where the registry gives one.

  • Novartis Investigative Site

    Bruges, Belgium

  • Novartis Investigative Site

    Ghent, Belgium

  • Novartis Investigative Site

    Mons, Belgium

  • Novartis Investigative Site

    Genk, Belgium, Belgium

  • Novartis Investigative Site

    Juiz de Fora, Minas Gerais, Brazil

  • Novartis Investigative Site

    Porto Alegre, Rio Grande do Sul, Brazil

  • Novartis Investigative Site

    Barretos, São Paulo, Brazil

  • Novartis Investigative Site

    Bogota, Cundinamarca, Colombia

  • Novartis Investigative Site

    Bogota, Cundinamarca, Colombia

  • Novartis Investigative Site

    Chía, Cundinamarca, Colombia

  • Novartis Investigative Site

    Bucaramanga, Santander Department, Colombia

  • Novartis Investigative Site

    Prague, Czechia

  • Novartis Investigative Site

    Prague, Czechia

  • Novartis Investigative Site

    Prague, Czechia

  • Novartis Investigative Site

    Uherské Hradiště, Czechia

  • Novartis Investigative Site

    Chambray-lès-Tours, France

  • Novartis Investigative Site

    Le Mans, France

  • Novartis Investigative Site

    Nice, France

  • Novartis Investigative Site

    Paris, France

  • Novartis Investigative Site

    Bad Doberan, Germany

  • Novartis Investigative Site

    Berlin, Germany

  • Novartis Investigative Site

    Berlin, Germany

  • Novartis Investigative Site

    Hamburg, Germany

  • Novartis Investigative Site

    Herne, Germany

  • Novartis Investigative Site

    Ratingen, Germany

  • Novartis Investigative Site

    Kistarcsa, Hungary

  • Novartis Investigative Site

    Miskolc, Hungary

  • Novartis Investigative Site

    Szeged, Hungary

  • Novartis Investigative Site

    Veszprém, Hungary

  • Novartis Investigative Site

    Székesfehérvár, Fejér, Hungary

  • Novartis Investigative Site

    Debrecen, Hajdu Bihar Megye, Hungary

  • Novartis Investigative Site

    Kfar Saba, Israel

  • Novartis Investigative Site

    Ramat Gan, Israel

  • Novartis Investigative Site

    Tel Aviv, Israel

  • Novartis Investigative Site

    Ancona, AN, Italy

  • Novartis Investigative Site

    Torino, TO, Italy

  • Novartis Investigative Site

    Negrar, VR, Italy

  • Novartis Investigative Site

    Verona, VR, Italy

  • Novartis Investigative Site

    Kuala Lumpur, Malaysia

  • Novartis Investigative Site

    Chihuahua City, Chihuahua, Mexico

Showing 40 of 61 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.